Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NTR-441 in Healthy Adults and COVID-19
NCT04941183Phase 1Terminated
- Sponsor
- Neutrolis, Inc.
- Start
- Apr 2021
- Primary completion
- Dec 2022
- Modality
- Therapeutic Enzymes, Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing NTR-441 with Placebo (2 arms). Primary endpoint: Safety and tolerability of single and multiple ascending doses at 60 days. Started Apr 2021; status: terminated.
02
Drugs
NTR-441
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04941183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04941183.